Opinion · 29 Jun 2025
Short communicationPublished 20 Oct 2021
PD-L1 mRNA Character in Plasma-Derived Exosomes is Correlated with Acknowledgment to Anti-PD-1 Antibodies in Melanoma and NSCLC
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
PD-L1 articulation in tumour tissues is broadly used to choose patients to get hostile to PD-1/PD-L1 antibodies, yet information is missing on the relationship of plasma PD-L1 levels with the impact of treatments. Immunotherapy has generously worked on the clinical result of a few tumours, including diseases inadequately receptive to chemotherapy. PD-L1 appraisal in tumour tissue (i.e., NSCLC) permits to distinguish a patient populace with higher probability of reaction concerning chemotherapy. In any case, changes in the movement of sign transduction pathways (i.e., MAPK) may influence PD-L1 levels, in this manner disabling its prescient worth whenever evaluated on a solitary tissue biopsy.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Oncology and Cancer Research.
Opinion · 29 Jun 2025
Molecular Biomarkers for Early Detection and Prognosis of Breast Cancer
Commentary · 29 Jun 2025
Targeted Therapy in Non-Small Cell Lung Cancer: Current Landscape and Future Directions
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Oncology and Cancer Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Ashley Taylor”
